|
Jul 1
|
Adagene announces up to $25 million strategic investment from Sanofi
|
|
Jun 30
|
Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment
|
|
Jun 30
|
Hedge Fund Strategy Built on Catastrophes Taps Hot New Trend
|
|
Jun 30
|
ESTEVE to acquire medicine to treat medullary thyroid cancer
|
|
Jun 30
|
Press release: Availability of the Q2 2025 Aide mémoire
|
|
Jun 30
|
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
|
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
|
Jun 26
|
Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
|
|
Jun 25
|
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
|
|
Jun 25
|
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
|
|
Jun 25
|
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
|
|
Jun 25
|
United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption
|
|
Jun 25
|
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
|
|
Jun 24
|
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
|
|
May 23
|
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
|
|
May 22
|
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
|
|
May 22
|
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
|